Previous 10 | Next 10 |
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista TM (sotagliflozin) and the settlement of its related disputes with S...
In March, the Food and Drug Administration issued a complete response letter -- the agency's euphemism for a rejection letter -- to Sanofi (NASDAQ: SNY) and Lexicon Pharmaceuticals (NASDAQ: LXRX) for their application to approve Zynquista as a treatment for type 1 diabetes. A few months...
THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the following conference: 2019 W...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) is up 4.6% after hours, rebounding off a 6.4% decline today, following disclosure that its president and CEO, Lonnel Coats, made several stock purchases over the past couple of business days. More news on: Lexicon Pharmaceuticals, Inc., Healthcare ...
Arcadia Biosciences (NASDAQ: RKDA ) +62% on USDA OK of drought-tolerant soybean strain. More news on: Arcadia Biosciences, Inc., Puma Biotechnology, Inc., Callaway Golf Company, Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) is up 7% premarket on light volume in response to pooled data from its inTandem1 and inTandem2 clinical trials evaluating Zynquista (sotagliflozin) in adult type 1 diabetics. The results were recently published in the journal Diabetes ...
Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced p...
Beaten down biopharma Lexicon Pharmaceuticals ( LXRX +13.7% ) perks up on increased volume, bucking the broad market's sour mood. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Lexicon Pharmaceuticals ( LXRX ) management reported earnings for the second quarter on July 31 and provided a little more context and detail about the situation with Sanofi ( SNY ) regarding the latter’s attempt to exit the development and marketing collaboration for SGLT-1/2 drug ...
Lexicon Pharmaceuticals, Inc. ( LXRX ) has been badly pummeled this week. It has dropped from last week's close of $5.69 to $1.35 on Wednesday after Sanofi ( SNY ) terminated its collaboration with it to develop, manufacture and commercialize Zynquista for diabetes and Q2 results that re...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...